Alleviating Cancer Drug Toxicity by Inhibiting a Bacterial Enzyme
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Blocking Interfering Microbes: Irinotecan is a widely used anticancer pro-drug that is converted in the liver into the active form, but when it gets into the gut, the normally benign microbial flora can convert it into the toxic form, which kills the rapidly multiplying gut epithelium as it would kill rapidly dividing tumor cells, and thus causes diarrhea. Wallace et al. (p. 831 ; see the Perspective by Patel and Kaufmann ) used high-throughput screening to identify inhibitors that target the offending bacterial enzyme, β-glucuronidase, without killing the bacteria or affecting orthologous mammalian enzymes. Crystal structures revealed the molecular basis of selectivity, and in vivo studies showed that an inhibitor protected mice from irinotecan-induced toxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Taken together, this functional metabolic repertoire includes the capacity for clinically relevant activation (e.g., sulfasalazine) (Peppercorn and Goldman, 1972b), reactivation (e.g., irinotecan/SN-38) (Wallace et al., 2010), and detoxification (e.g., digoxin) (Haiser et al., 2013) of xenobiotics with broad implications for drug action and toxicity (see Table 1).”
From Gut reactions: Breaking down xenobiotic–microbiome interactions (2019) · cites this paper as Wallace et al., 2010
The cited source says what the claim attributes to it.
In the citing paper
“Toxic or adverse consequences can also ensue, as is the case for irinotecan (Wallace et al., 2010)”
From Gut reactions: Breaking down xenobiotic–microbiome interactions (2019) · cites this paper as Wallace et al., 2010
In the citing paper
“Notably, β-glucuronidase inhibitors are capable of rescuing mice from drug toxicity.”
From The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism (2016) · cites this paper as [146]
In the citing paper
“This specificity towards the bacterial enzymes was revealed with the assistance of crystallography and bioinformatics, which demonstrated that these inhibitors interacted with a “bacterial loop” that is highly conserved and well distributed across the gut bacteria enzymes, but is absent from the mammalian enzyme146.”
From The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism (2016) · cites this paper as [146]
In the citing paper
“The answer appears to be yes for the bacterial β-glucuronidases, for which multiple inhibitors now exist that have minimal impact on the mammalian homolog143–146.”
From The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism (2016) · cites this paper as [146]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zhang, J.-H., Chung, T. D. Y., & Oldenburg, K. R. (1999) · SLAS Discovery · doi:10.1177/108705719900400206 · Cited by 6,847
Turnbaugh, P. J., Ley, R. E., Hamady, M., Fraser-Liggett, C. M., Knight, R., & Gordon, J. I. (2007) · Nature · doi:10.1038/nature06244 · Cited by 6,091
Antibacterial resistance worldwide: causes, challenges and responses
Levy, S. B., & Marshall, B. (2004) · Nature Medicine · doi:10.1038/nm1145 · Cited by 4,052
Gut flora in health and disease
Guarner, F., & Malagelada, J.-R. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12489-0 · Cited by 3,365
Cohen, S. H., Gerding, D. N., Johnson, S., Kelly, C. P., Loo, V. G., McDonald, L. C., Pepin, J., & Wilcox, M. H. (2010) · Infection Control & Hospital Epidemiology · doi:10.1086/651706 · Cited by 2,942
Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I.
Hsiang, Y. H., Hertzberg, R., Hecht, S., & Liu, L. F. (1985) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)38654-4 · Cited by 2,362
Topoisomerase I inhibitors: camptothecins and beyond
Pommier, Y. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1977 · Cited by 2,277
CDD: specific functional annotation with the Conserved Domain Database
Marchler-Bauer, A., Anderson, J. B., Chitsaz, F., Derbyshire, M. K., DeWeese-Scott, C., Fong, J. H., Geer, L. Y., Geer, R. C., Gonzales, N. R., Gwadz, M., et al. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn845 · Cited by 1,071
Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).
Mathijssen, R. H. J., van Alphen, R. J., Verweij, J., Loos, W. J., Nooter, K., Stoter, G., & Sparreboom, A. (2001) · PubMed · Cited by 740
Three-dimensional structure of β-galactosidase from E. coli.
Jacobson, R. H., Zhang, X.-J., DuBose, R. F., & Matthews, B. W. (1994) · Nature · doi:10.1038/369761a0 · Cited by 600
Research works printed but not linked: 4
- Mathijssen RHJ Clin Cancer Res 7 2182 2001 11489791
- Basińska A Floriańczyk B Ann Univ Mariae Curie Sklodowska Med 58 386 2003 15323223
- Jain S Nat Struct Mol Biol 3 375 1996 · DOI · Paper page
- Brattain MG Fine WD Khaled FM Thompson J Brattain DE Cancer Res 41 1751 1981 7214343
Cited by
Items 401–500 of 1,001
Impacts of gut microbiota alteration on age-related chronic liver diseases
Adhikary, S., Esmeeta, A., Dey, A., Banerjee, A., Saha, B., Gopan, P., Duttaroy, A. K., & Pathak, S. (2023) · Digestive and Liver Disease · doi:10.1016/j.dld.2023.06.017 · Cited by 38
Fernández-Murga, M. L., Gil-Ortiz, F., Serrano-García, L., & Llombart‐Cussac, A. (2023) · Pathogens · doi:10.3390/pathogens12091086 · Cited by 37
Orally Administered Drugs and Their Complicated Relationship with Our Gastrointestinal Tract
Bashiardes, S., & Christodoulou, C. (2024) · Microorganisms · doi:10.3390/microorganisms12020242 · Cited by 38
Pharma[e]cology: How the Gut Microbiome Contributes to Variations in Drug Response
Trepka, K. R., Olson, C. A., Upadhyay, V., Zhang, C., & Turnbaugh, P. J. (2024) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-022724-100847 · Cited by 36
The intestinal microbiome and surgical disease
Krezalek, M. A., Skowron, K. B., Guyton, K. L., Shakhsheer, B. A., Hyoju, S. K., & Alverdy, J. C. (2016) · Current Problems in Surgery · doi:10.1067/j.cpsurg.2016.06.001 · Cited by 39
Lozenov, S., Krastev, B. M., Nikolaev, G., Peshevska-Sekulovska, M., Peruhova, M., & Velikova, T. V. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065978 · Cited by 36
Bedarf, J. R., Hildebrand, F., Coelho, L. P., Sunagawa, S., Bahram, M., Goeser, F., Bork, P., & Wüllner, U. (2017) · Genome Medicine · doi:10.1186/s13073-017-0451-z · Cited by 37
Gut Microbiome–Colorectal Cancer Relationship
Yadav, D., Sainatham, C., Filippov, E., Kanagala, S. G., Ishaq, S. M., & Jayakrishnan, T. (2024) · Microorganisms · doi:10.3390/microorganisms12030484 · Cited by 41
Yu, A., Ingelman‐Sundberg, M., Cherrington, N. J., Aleksunes, L. M., Zanger, U. M., Xie, W., Jeong, H., Morgan, E. T., Turnbaugh, P. J., Klaassen, C. D., et al. (2017) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2016.12.006 · Cited by 37
Self-citationLv, B., Sun, H., Huang, S., Feng, X., Jiang, T., & Li, C. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.801910 · Cited by 35
Hawkins, K. G., Casolaro, T. C., Brown, J. A., Edwards, D. A., & Wikswo, J. P. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1870 · Cited by 39
Feng, W., Liu, J., Huang, L., Tan, Y., & Peng, C. Y. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.111047 · Cited by 37
A structural metagenomics pipeline for examining the gut microbiome
Walker, M. E., Simpson, J. B., & Redinbo, M. R. (2022) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2022.102416 · Cited by 36
Self-citationThe Gut Microbiota in Causation, Detection, and Treatment of Cancer
Murphy, C. L., O’Toole, P. W., & Shanahan, F. (2019) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000075 · Cited by 36
Groestlinger, J., Spindler, V., Pahlke, G., Rychlik, M., Favero, G. D., & Marko, D. (2022) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.1c00364 · Cited by 35
Malwe, A. S., Srivastava, G. N., & Sharma, V. K. (2023) · Journal of Molecular Biology · doi:10.1016/j.jmb.2023.168056 · Cited by 35
Guo, L., Katiyo, W., Lu, L., Zhang, X., Wang, M., Yan, J., Ma, X., Yang, R., Zou, L., & Zhao, W. (2018) · Comprehensive Reviews in Food Science and Food Safety · doi:10.1111/1541-4337.12353 · Cited by 34
Discovery and Characterization of FMN-Binding β-Glucuronidases in the Human Gut Microbiome
Pellock, S. J., Walton, W. G., Ervin, S. M., Torres-Rivera, D., Creekmore, B. C., Bergan, G., Dunn, Z. D., Ли, Б., Tripathy, A., & Redinbo, M. R. (2019) · Journal of Molecular Biology · doi:10.1016/j.jmb.2019.01.013 · Cited by 34
Self-citationMicrobiota alter metabolism and mediate neurodevelopmental toxicity of 17β-estradiol
Catron, T. R., Swank, A., Wehmas, L. C., Phelps, D. W., Keely, S. P., Brinkman, N. E., McCord, J. P., Singh, R. R., Sobus, J. R., Wood, C. E., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-43346-9 · Cited by 35
Genomics and metagenomics of colorectal cancer
Ng, C., Li, H., Wu, W. K. K., Wong, S. H., & Yu, J. Q. (2019) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2019.06.04 · Cited by 35
Wang, Y., Qin, S., Jia, J., Huang, L., Li, F., Jin, F., Ren, Z., & Wang, Y. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.01343 · Cited by 34
Association of the microbiome with colorectal cancer development (Review)
Abdulla, M., Agarwal, D., Singh, J. K., Traiki, T. A. B., Pandey, M. K., Ahmad, R., & Srivastava, S. K. (2021) · International Journal of Oncology · doi:10.3892/ijo.2021.5197 · Cited by 35
Can preclinical drug development help to predict adverse events in clinical trials?
Chi, L. H., Burrows, A. D., & Anderson, R. L. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.08.010 · Cited by 34
Kumar, K., Jaiswal, S. K., Dhoke, G. V., Srivastava, G. N., Sharma, A. K., & Sharma, V. K. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26638 · Cited by 36
Xia, Y., DiPrimio, N., Keppel, T. R., Vo, B., Fraser, K., Battaile, K. P., Egan, C., Bystroff, C., Lovell, S., Weis, D. D., et al. (2013) · Journal of the American Chemical Society · doi:10.1021/ja407644b · Cited by 33
Microbial metabolism marvels: a comprehensive review of microbial drug transformation capabilities
Martinelli, F., & Thiele, I. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2387400 · Cited by 33
Bar-Zeev, M., Kelmansky, D., Assaraf, Y. G., & Livney, Y. D. (2018) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2018.10.018 · Cited by 33
Microbiome and host crosstalk: A new paradigm to cancer therapy
Singh, A. K., Nayak, N., Rathi, P., Verma, D., Sharma, R., Chaudhary, A., Agarwal, A., Tripathi, Y. B., & Garg, N. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.05.014 · Cited by 35
The Gut Microbiome and Xenobiotics: Identifying Knowledge Gaps
Sutherland, V. L., McQueen, C. A., Mendrick, D. L., Gulezian, D., Cerniglia, C. E., Foley, S. L., Forry, S., Khare, S., Liang, X., Manautou, J. E., et al. (2020) · Toxicological Sciences · doi:10.1093/toxsci/kfaa060 · Cited by 33
Panebianco, C., Ciardiello, D., Villani, A., Maiorano, B. A., Latiano, T. P., Maiello, E., Perri, F., & Pazienza, V. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.11.007 · Cited by 33
The effects of micro RNA on the absorption, distribution, metabolism and excretion of drugs
He, Y., Chevillet, J. R., Liu, G., Kim, T. K., & Wang, K. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12968 · Cited by 37
Targeting colorectal cancer-associated bacteria: A new area of research for personalized treatments
Faïs, T., Delmas, J., Cougnoux, A., Dalmasso, G., & Bonnet, R. (2016) · Gut Microbes · doi:10.1080/19490976.2016.1155020 · Cited by 34
Deng, C., Deng, B., Jia, L., Tan, H., Zhang, P., Liu, S., Zhang, Y., Song, A., & Pan, L. (2017) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2017/7350251 · Cited by 35
Zhang, P.-F., & Xie, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1362133 · Cited by 39
Prijovich, Z. M., Burnouf, P., Chou, H.-C., Huang, P.-T., Chen, K., Cheng, T., Leu, Y.-L., & Roffler, S. R. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00771 · Cited by 32
Genetic Polymorphisms Affecting Drug Metabolism
Daly, A. K. (2012) · Advances in pharmacology · doi:10.1016/b978-0-12-398339-8.00004-5 · Cited by 35
Mickoleit, F., & Schüler, D. (2017) · Advanced Biosystems · doi:10.1002/adbi.201700109 · Cited by 32
GUT Microbiome-GUT Dysbiosis-Arterial Hypertension: New Horizons
Katsi, V. K., Didagelos, M., Skevofilax, S., Armenis, I., Kartalis, A. N., Vlachopoulos, C. V., Karvounis, H. I., & Tousoulis, D. M. (2018) · Current Hypertension Reviews · doi:10.2174/1573402114666180613080439 · Cited by 32
Exploring the Involvement of Gut Microbiota in Cancer Therapy-Induced Cardiotoxicity
Kunika, Frey, N., & Rangrez, A. Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087261 · Cited by 34
Chapadgaonkar, S. S., Bajpai, S., & Godbole, M. S. (2023) · Cancer Reports · doi:10.1002/cnr2.1847 · Cited by 41
He, J., Li, H., Jia, J., Liu, Y., Zhang, N., Wang, R., Qu, W., Liu, Y., & Jia, L. (2023) · Molecular Biomedicine · doi:10.1186/s43556-023-00157-9 · Cited by 34
Li, Y., Liu, M., Zhou, J., Hou, B., Su, X.-H., Liu, Z., Yuan, J., & Li, M. (2019) · Beneficial Microbes · doi:10.3920/bm2018.0122 · Cited by 34
Harnessing the microbiome for cancer therapy
Hajjar, R., Mars, R. A. T., & Kashyap, P. (2026) · Nature Reviews Microbiology · doi:10.1038/s41579-025-01268-6 · Cited by 34
Microbial Glucuronidase Inhibition Reduces Severity of Diclofenac-Induced Anastomotic Leak in Rats
Yauw, S. T. K., Arron, M. N. N., Lomme, R. M. L. M., van den Broek, P., Greupink, R., Bhatt, A. P., Redinbo, M. R., & van Goor, H. (2018) · Surgical Infections · doi:10.1089/sur.2017.245 · Cited by 31
Self-citationGut microbiome metagenomics to understand how xenobiotics impact human health
Mesnage, R., Antoniou, M. N., Tsoukalas, D., Goulielmos, G. N., & Tsatsakis, A. M. (2018) · Current Opinion in Toxicology · doi:10.1016/j.cotox.2019.02.002 · Cited by 34
Imai, H., Saijo, K., Komine, K., Otsuki, Y., Ouchi, K., Sato, Y., Okita, A., Takahashi, M., Takahashi, S. I., Shirota, H., et al. (2019) · Cancer Management and Research · doi:10.2147/cmar.s215697 · Cited by 31
Gut Microbiota and Cancer of the Host: Colliding Interests
Baffy, G. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-34025-4_5 · Cited by 33
Dong, J., Gao, H.-L., Wang, W., Yu, X., & Liu, L. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188484 · Cited by 31
Yu, Q., Jobin, C., & Thomas, R. M. (2021) · Neoplasia · doi:10.1016/j.neo.2020.12.008 · Cited by 33
Self-citationCheng, Z., Sun, H., Sidhu, H. S., Sy, N. D., Wang, X., & Gan, J. J. (2021) · Environmental Science & Technology · doi:10.1021/acs.est.0c07232 · Cited by 33
Dingenen, L. V., Segers, C., Wouters, S., Mysara, M., Leys, N., Kumar‐Singh, S., Malhotra‐Kumar, S., & Houdt, R. V. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1298264 · Cited by 31
Structural Photodynamics of Camptothecin, an Anticancer Drug in Aqueous Solutions
di Nunzio, M. R., Cohen, B., & Douhal, A. (2011) · The Journal of Physical Chemistry A · doi:10.1021/jp201749u · Cited by 31
Cai, J., Auster, A., Cho, S., & Lai, Z. (2023) · Journal of Advanced Research · doi:10.1016/j.jare.2023.07.002 · Cited by 31
Wang, C., Teng, X., Wang, C., Liu, B., Zhou, R., Xu, X., Qiu, H., Fu, Y., Sun, R., Liang, Z., et al. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.155040 · Cited by 31
Gao, R., Yue, B., Lv, C., Geng, X., Yu, Z., Wang, H., Zhang, B., Ai, F., Wang, Z., Liu, D., et al. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.09.018 · Cited by 31
Self-citationRzeczycki, P., Pęciak, O., Plust, M., & Droździk, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262411897 · Cited by 30
Low Cerebral Exposure Cannot Hinder the Neuroprotective Effects of Panax Notoginsenosides
Li, H., Xiao, J., Li, X., Chen, H., Kang, D., Shao, Y., Shen, B., Zhu, Z., Yin, X., Xie, L. Y., et al. (2017) · Drug Metabolism and Disposition · doi:10.1124/dmd.117.078436 · Cited by 30
Bruneau, A., Baylatry, M., Joly, A. C., & Sokol, H. (2017) · Bulletin du Cancer · doi:10.1016/j.bulcan.2017.10.025 · Cited by 36
Activity-Based Protein Profiling—Enabling Multimodal Functional Studies of Microbial Communities
Whidbey, C., & Wright, A. (2018) · Current topics in microbiology and immunology · doi:10.1007/82_2018_128 · Cited by 31
Cheng, Z., Sun, H., Sidhu, H. S., Sy, N. D., & Gan, J. J. (2020) · Environmental Pollution · doi:10.1016/j.envpol.2020.114886 · Cited by 31
Living Therapeutics: The Next Frontier of Precision Medicine
Kelly, V. W., Liang, B. K., & Sirk, S. J. (2020) · ACS Synthetic Biology · doi:10.1021/acssynbio.0c00444 · Cited by 30
Boeravinone B alleviates gut dysbiosis during myocardial infarction‐induced cardiotoxicity in rats
Chen, Y., Peng, L., Shi, S., Guo, G. F., & Wen, H. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16620 · Cited by 30
Su, Y.-C., Cheng, T.-C., Leu, Y.-L., Roffler, S. R., Wang, J., Chuang, C., Kao, C.-H., Chen, K., Wang, H.-E., & Cheng, T. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0212 · Cited by 30
Self-citationEngineering the Microbiome to Prevent Adverse Events: Challenges and Opportunities
Khan, S. M., Hauptman, R., & Kelly, L. (2020) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-031620-031509 · Cited by 32
Wild immunology: converging on the real world
Babayan, S. A., Allen, J. E., Bradley, J. E., Geuking, M. B., Graham, A. L., Grencis, R. K., Kaufman, J., McCoy, K. D., Paterson, S., Smith, K. G. C., et al. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.06251.x · Cited by 37
Synthesis of uronic-Noeurostegine – a potent bacterial β-glucuronidase inhibitor
Rasmussen, T. S., Koldsø, H., Nakagawa, S., Kato, A., Schiøtt, B., & Jensen, H. H. (2011) · Organic & Biomolecular Chemistry · doi:10.1039/c1ob06038d · Cited by 30
A High Throughput Assay for Discovery of Bacterial β-Glucuronidase Inhibitors
Ahmad, S., Hughes, M. A., Lane, K. T., Redinbo, M. R., Yeh, L.-A., & Scott, J. E. (2011) · Current Chemical Genomics · doi:10.2174/1875397301105010013 · Cited by 29
Self-citationThe Parkinson’s disease drug entacapone disrupts gut microbiome homeostasis via iron sequestration
Pereira, F. C., Ge, X., Kristensen, J. M., Kirkegaard, R. H., Maritsch, K., Szamosvári, D., Imminger, S., Seki, D., Shazzad, J. B., Zhu, Y., et al. (2024) · Nature Microbiology · doi:10.1038/s41564-024-01853-0 · Cited by 30
Expansion of a bacterial operon during cancer treatment ameliorates fluoropyrimidine toxicity
Trepka, K. R., Kidder, W. A., Kyaw, T. S., Halsey, T. M., Olson, C. A., Ortega, E. F., Noecker, C. A., Upadhyay, V., Stanfield, D., Steiding, P., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adq8870 · Cited by 30
Chen, L., Tai, W., Brar, M. S., Leung, F. C.-C., & Hsiao, W. L. W. (2015) · PLoS ONE · doi:10.1371/journal.pone.0126807 · Cited by 31
Gut microbiome: A possible common therapeutic target for treatment of atherosclerosis and cancer
Wu, W., Ivanova, E. A., & Orekhov, A. N. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.06.017 · Cited by 29
Luo, X., Yu, Z., Yue, B., Ren, J., Zhang, J., Mani, S., Wang, Z., & Dou, W. (2020) · Pharmaceutical Biology · doi:10.1080/13880209.2020.1812673 · Cited by 31
Self-citationData mining the human gut microbiota for therapeutic targets
Collison, M., Hirt, R. P., Wipat, A., Nakjang, S., Sanséau, P., & Brown, J. R. (2012) · Briefings in Bioinformatics · doi:10.1093/bib/bbs002 · Cited by 32
Tini, S., Baima, J., Pigni, S., Antoniotti, V., Caputo, M., Palma, E. D., Cerbone, L., Grosso, F., Vecchia, M. L., Bona, E., et al. (2025) · Nutrients · doi:10.3390/nu17172898 · Cited by 30
Molan, A., & Mahdy, A. S. (2014) · IOSR Journal of Dental and Medical Sciences · doi:10.9790/0853-13527277 · Cited by 28
Tian, X., Yan, J., Sun, C., Li, J., Ning, J., Wang, C., Huo, X., Zhao, W., Yu, Z., Feng, L., et al. (2021) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2021.109453 · Cited by 28
Targeting the gut microbiota to alleviate chemotherapy-induced toxicity in cancer
Xu, Y., Du, H., Chen, Y., Ma, C., Zhang, Q., Li, H., Xie, Z., & Hong, Y. (2023) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2023.2233605 · Cited by 28
OptZyme: Computational Enzyme Redesign Using Transition State Analogues
Grisewood, M. J., Gifford, N. P., Pantazes, R. J., Li, Y., Cirino, P. C., Janik, M. J., & Maranas, C. D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0075358 · Cited by 31
He, Z., Xie, H., Xu, H., Wu, J., Zeng, W., He, Q., Jobin, C., Jin, S., & Lan, P. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2319511 · Cited by 27
Self-citationConstantin, M., Chifiriuc, M. C., Mihăescu, G., Corcionivoschi, N., Burlibaşa, L., Bleoţu, C., Tudorache, S. I., Mitache, M. M., Filip, R., Munteanu, S.-G., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1373504 · Cited by 27
Guo, Y., Wang, J., Wu, X., Qiao, Q., Liao, T., Li, L., Xu, Z., Zheng, D., Kuang, Y., Yu, W., et al. (2025) · Nano Today · doi:10.1016/j.nantod.2025.102848 · Cited by 28
Pathak, B. P., Zhao, S., Manoharan, M., & Srivastava, V. (2019) · 3 Biotech · doi:10.1007/s13205-019-1690-z · Cited by 27
The gut microbiome in solid organ transplantation
Arassi, M. B., Zeller, G., Karcher, N., Zimmermann, M., & Tönshoff, B. (2020) · Pediatric Transplantation · doi:10.1111/petr.13866 · Cited by 27
Drug–Microbiota Interaction in Colon Cancer Therapy: Impact of Antibiotics
Mohamed, A. A., Menon, H., Chulkina, M., Yee, N. S., & Pinchuk, I. V. (2021) · Biomedicines · doi:10.3390/biomedicines9030259 · Cited by 27
The Role of Gut Microbiota in Modulating Tumor Growth and Anticancer Agent Efficacy
Kim, J.-H., & Lee, H. K. (2021) · Molecules and Cells · doi:10.14348/molcells.2021.0032 · Cited by 29
Shi, L., Wu, X., Li, T., Wu, Y., Song, L., Zhang, W., Yin, L., Wu, Y., Han, W., & Yang, Y. (2021) · Nanoscale Advances · doi:10.1039/d1na00838b · Cited by 27
Meng, J., Abu, Y. F., Zhang, Y., Zhou, Y., Xie, Y., Yan, Y., Tao, J., Ramakrishnan, S., Chen, C., & Roy, S. (2023) · British Journal of Pharmacology · doi:10.1111/bph.16020 · Cited by 27
Microbial β-glucuronidases drive human periodontal disease etiology
Lietzan, A. D., Simpson, J. B., Walton, W. G., Jariwala, P. B., Xu, Y., Boynton, M. H., Liu, J., & Redinbo, M. R. (2023) · Science Advances · doi:10.1126/sciadv.adg3390 · Cited by 27
Self-citationComputational tools for modeling xenometabolism of the human gut microbiota
Klünemann, M., Schmid, M., & Patil, K. R. (2014) · Trends in biotechnology · doi:10.1016/j.tibtech.2014.01.005 · Cited by 29
wild-type choline TMA lyase in complex with betaine aldehyde
Funk, M. A., & Drennan, C. L. (2018) · Worldwide Protein Data Bank · doi:10.2210/pdb6nd3/pdb · Cited by 27
Gut microbiome and cardiometabolic comorbidities in people living with HIV
Trøseid, M., Nielsen, S. D., & Vujkovic-Cvijin, I. (2024) · Microbiome · doi:10.1186/s40168-024-01815-y · Cited by 27
Cancer and the Microbiome of the Human Body
Herrera‐Quintana, L., Vázquez‐Lorente, H., López-Garzón, M., Cortés‐Martín, A., & Plaza‐Díaz, J. (2024) · Nutrients · doi:10.3390/nu16162790 · Cited by 27
Qin, W., Wang, S., Min, Y., Liu, X., Fang, J., Lang, J., & Chen, M. (2025) · BMC Women s Health · doi:10.1186/s12905-025-03599-1 · Cited by 29
The gut microbiota: an emerging modulator of drug resistance in hepatocellular carcinoma
Yao, J., Ning, B., & Ding, J. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2473504 · Cited by 28
Amoxapine Demonstrates Incomplete Inhibition of β-Glucuronidase Activity from Human Gut Microbiota
Yang, W., Wei, B., & Yan, R. (2017) · SLAS DISCOVERY · doi:10.1177/2472555217725264 · Cited by 27
Chattopadhyay, I., Nandi, D., & Nag, A. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.07.012 · Cited by 27
Beta-Glucuronidase Inhibition by Constituents of Mulberry Bark
Bai, Y., Chen, L., Cao, Y., Hou, X.-D., Jia, S.-N., Zhou, Q., He, Y., & Hou, J. (2021) · Planta Medica · doi:10.1055/a-1402-6431 · Cited by 27
Zhuang, H., Jing, N., Wang, L., Jiang, G., & Liu, Z. (2021) · Nutrients · doi:10.3390/nu13082700 · Cited by 26
Pharmacomicrobiomics in Anticancer Therapies: Why the Gut Microbiota Should Be Pointed Out
Conti, G., D’Amico, F., Fabbrini, M., Brigidi, P., Barone, M., & Turroni, S. (2022) · Genes · doi:10.3390/genes14010055 · Cited by 28
Heterogeneity in precision oncology
Tomasik, B., Garbicz, F., Braun, M., Bieńkowski, M., & Jassem, J. (2023) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2023.23 · Cited by 31
Metadata
- Authors
- Wallace, B. D., Wang, H., Lane, K. T., Scott, J. E., Orans, J., Koo, J. S., Venkatesh, M., Jobin, C., Yeh, L.-A., Mani, S., & Redinbo, M. R.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Albert Einstein College of Medicine (US)
- North Carolina Central University (US)
- ORCID
- Venue
- Science
- Published
- 2010-11-05
- Volume
- 330
- Issue
- 6005
- Pages
- 831-835
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC3110694
- OpenAlex
- W2140145798
- Cited by
- 1,080
- References
- 39
- Citations by year
- 2026: 97 · 2025: 80 · 2024: 103 · 2023: 101 · 2022: 92 · 2021: 92 · 2020: 100 · 2019: 82 · 2018: 70 · 2017: 67 · 2016: 47 · 2015: 33 · 2014: 34 · 2013: 28 · 2012: 29
- FWCI
- 25.42
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- Damon Runyon Cancer Research Foundation
- Golden LEAF Foundation
- National Institutes of Health
- National Cancer Institute (CA 127231, R01CA161879, R01CA127231, CA98468, R01CA098468)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK073338)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Bioactive Compounds and Antitumor Agents
- Keywords
- irinotecan, chemotherapy-induced diarrhea, enzyme inhibitors, gut microbiota, commensal bacteria, substrate specificity, crystal structure, high-throughput screening, oral administration, colon cancer, drug toxicity
- MeSH terms
- Irinotecan, Animals, Antineoplastic Agents, Phytogenic, Bacteria, Anaerobic, Camptothecin, Colon, Diarrhea, Drug Evaluation, Preclinical, Enzyme Inhibitors, Escherichia coli, Female, Glucuronidase, Humans, Intestinal Mucosa, Mice, Inbred BALB C, Models, Molecular, Prodrugs, Protein Conformation, Crystallography, X-Ray, Escherichia coli Proteins, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.